(Q34112937)

31 July 2017

1 reference

title

Inhaled salmeterol/fluticasone propionate combination: a review of its use in persistent asthma (English)

1 reference

31 July 2017

0 references

1

A Markham

0 references

author name string

A Markham

series ordinal

1

1 reference

31 July 2017

B Jarvis

series ordinal

2

1 reference

31 July 2017

publication date

1 November 2000

1 reference

31 July 2017

1 reference

31 July 2017

volume

60

1 reference

31 July 2017

issue

5

1 reference

31 July 2017

page(s)

1207-1233

1 reference

Improving patient compliance with asthma therapy

31 July 2017

cites work

1 reference

12 December 2020

Pharmacokinetics and systemic effects of inhaled fluticasone propionate in healthy subjects

1 reference

12 December 2020

The complementary role of glucocorticosteroids and long-acting beta-adrenergic agonists

1 reference

12 December 2020

Development of fluticasone propionate and comparison with other inhaled corticosteroids

1 reference

12 December 2020

Salmeterol xinafoate. A review of its pharmacological properties and therapeutic potential in reversible obstructive airways disease

1 reference

12 December 2020

Distribution of inhaled fluticasone propionate between human lung tissue and serum in vivo

1 reference

12 December 2020

1 reference

12 December 2020

Inhaled salmeterol and fluticasone: a study comparing monotherapy and combination therapy in asthma

1 reference

12 December 2020

Salmeterol/fluticasone propionate (50/500 microg) in combination in a Diskus inhaler (Seretide) is effective and safe in the treatment of steroid-dependent asthma

1 reference

12 December 2020

Salmeterol/fluticasone propionate combination

1 reference

12 December 2020

Patient factors and compliance with asthma therapy

1 reference

12 December 2020

Ligand-independent activation of the glucocorticoid receptor by beta2-adrenergic receptor agonists in primary human lung fibroblasts and vascular smooth muscle cells

1 reference

12 December 2020

Meta-analysis of increased dose of inhaled steroid or addition of salmeterol in symptomatic asthma (MIASMA).

1 reference

12 December 2020

Salmeterol added to inhaled corticosteroid therapy is superior to doubling the dose of inhaled corticosteroids: a randomized clinical trial.

1 reference

12 December 2020

Fluticasone alone or in combination with salmeterol vs triamcinolone in asthma.

1 reference

12 December 2020

Salmeterol. A review of its pharmacological properties and clinical efficacy in the management of children with asthma

1 reference

12 December 2020

Salmeterol/fluticasone propionate (50/100 microg) in combination in a Diskus inhaler (Seretide) is effective and safe in children with asthma

1 reference

12 December 2020

Comparison of addition of salmeterol to inhaled steroids with doubling of the dose of inhaled steroids

1 reference

12 December 2020

Salmeterol: a study by prescription-event monitoring in a UK cohort of 15,407 patients

1 reference

12 December 2020

Salmeterol/fluticasone propionate combination therapy 50/250 microg twice daily is more effective than budesonide 800 microg twice daily in treating moderate to severe asthma

1 reference

12 December 2020

Salmeterol/Fluticasone combination inhaler: a new, effective and well tolerated treatment for asthma

1 reference

12 December 2020

Inhaled fluticasone propionate. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in asthma

1 reference

12 December 2020

Concurrent use of salmeterol with inhaled corticosteroids is more effective than inhaled corticosteroid dose increases

1 reference

12 December 2020

The addition of salmeterol to fluticasone propionate versus increasing the dose of fluticasone propionate in patients with persistent asthma. Salmeterol Study Group

1 reference

12 December 2020

Salmeterol reduces the need for inhaled corticosteroid in steroid-dependent asthmatics

1 reference

12 December 2020

Combined salmeterol 50 microg and fluticasone propionate 250 microg in the diskus device for the treatment of asthma

1 reference

12 December 2020

Cost-effectiveness of salmeterol/fluticasone propionate combination product 50/250 microg twice daily and budesonide 800 microg twice daily in the treatment of adults and adolescents with asthma. International Study Group

1 reference

12 December 2020

Fluticasone propionate/salmeterol combination provides more effective asthma control than low-dose inhaled corticosteroid plus montelukast

1 reference

12 December 2020

Salmeterol and fluticasone propionate combined in a new powder inhalation device for the treatment of asthma: a randomized, double-blind, placebo-controlled trial

1 reference

12 December 2020

Comparison of inhaled salmeterol and oral zafirlukast in patients with asthma

1 reference

12 December 2020

Added salmeterol versus higher-dose corticosteroid in asthma patients with symptoms on existing inhaled corticosteroid. Allen & Hanburys Limited UK Study Group

1 reference

12 December 2020

Salmeterol and fluticasone propionate (50/250 microg) administered via combination Diskus inhaler: as effective as when given via separate Diskus inhalers

1 reference

12 December 2020

Inhaled fluticasone propionate: a review of its therapeutic efficacy at dosages < or = 500 microg/day in adults and adolescents with mild to moderate asthma

1 reference

12 December 2020

10.2165/00003495-200060050-00012

Identifiers

DOI

1 reference

Dimensions Publication ID

31 July 2017

1025336960

0 references

1 reference